Its Antibody Drug Works Against Omicron Variant, GSK Says
GlaxoSmithKline (GSK) said on Thursday that laboratory testing of the antibody-based Covid-19 treatment that it is developing in partnership with the United States based from Vir has shown that the medicine is effective against the Omicron variant of the novel coroanvirus. According to a statement made public by GSK, lab testing and a hamster research…







